Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Patterns of re-irradiation for recurrent gliomas and validation of a prognostic score.

Post CCB, Kramer MCA, Smid EJ, van der Weide HL, Kleynen CE, Heesters MAAM, Verhoeff JJC.

Radiother Oncol. 2018 Nov 13. pii: S0167-8140(18)33575-8. doi: 10.1016/j.radonc.2018.10.034. [Epub ahead of print]

PMID:
30446315
2.

Validation of an established prognostic score after re-irradiation of recurrent glioma.

Kessel KA, Hesse J, Straube C, Zimmer C, Schmidt-Graf F, Schlegel J, Meyer B, Combs SE.

Acta Oncol. 2017 Mar;56(3):422-426. doi: 10.1080/0284186X.2016.1276621. Epub 2017 Jan 11.

PMID:
28075197
3.

Reirradiation with concurrent bevacizumab for recurrent high-grade gliomas in adult patients.

Schernberg A, Dhermain F, Ammari S, Dumont SN, Domont J, Patrikidou A, Pallud J, Dezamis É, Deutsch É, Louvel G.

Cancer Radiother. 2018 Feb;22(1):9-16. doi: 10.1016/j.canrad.2017.06.013. Epub 2017 Dec 6.

PMID:
29217134
4.

Generation and validation of a prognostic score to predict outcome after re-irradiation of recurrent glioma.

Combs SE, Edler L, Rausch R, Welzel T, Wick W, Debus J.

Acta Oncol. 2013 Jan;52(1):147-52. doi: 10.3109/0284186X.2012.692882. Epub 2012 Jun 11.

PMID:
22686472
5.

Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy.

Grosu AL, Weber WA, Franz M, Stärk S, Piert M, Thamm R, Gumprecht H, Schwaiger M, Molls M, Nieder C.

Int J Radiat Oncol Biol Phys. 2005 Oct 1;63(2):511-9.

PMID:
16168843
6.

Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent high-grade gliomas.

Fogh SE, Andrews DW, Glass J, Curran W, Glass C, Champ C, Evans JJ, Hyslop T, Pequignot E, Downes B, Comber E, Maltenfort M, Dicker AP, Werner-Wasik M.

J Clin Oncol. 2010 Jun 20;28(18):3048-53. doi: 10.1200/JCO.2009.25.6941. Epub 2010 May 17. Erratum in: J Clin Oncol. 2010 Sep 20;28(27):4280.

7.

Re-irradiation for malignant glioma: Toward patient selection and defining treatment parameters for salvage.

Shen CJ, Kummerlowe MN, Redmond KJ, Martinez-Gutierrez JC, Usama SM, Holdhoff M, Grossman SA, Laterra JJ, Strowd RE, Kleinberg LR.

Adv Radiat Oncol. 2018 Jul 10;3(4):582-590. doi: 10.1016/j.adro.2018.06.005. eCollection 2018 Oct-Dec.

8.

Hypofractionated Stereotactic Radiotherapy as a Salvage Therapy for Recurrent High-Grade Gliomas: Single-Center Experience.

Reynaud T, Bertaut A, Farah W, Thibouw D, Crehange G, Truc G, Vulquin N.

Technol Cancer Res Treat. 2018 Jan 1;17:1533033818806498. doi: 10.1177/1533033818806498.

9.

Hypofractionated stereotactic radiotherapy for unifocal and multifocal recurrence of malignant gliomas.

McKenzie JT, Guarnaschelli JN, Vagal AS, Warnick RE, Breneman JC.

J Neurooncol. 2013 Jul;113(3):403-9. doi: 10.1007/s11060-013-1126-2. Epub 2013 Apr 16.

PMID:
23589034
10.
11.

Hypofractionated stereotactic radiotherapy and continuous low-dose temozolomide in patients with recurrent or progressive malignant gliomas.

Minniti G, Scaringi C, De Sanctis V, Lanzetta G, Falco T, Di Stefano D, Esposito V, Enrici RM.

J Neurooncol. 2013 Jan;111(2):187-94. doi: 10.1007/s11060-012-0999-9. Epub 2012 Nov 6.

PMID:
23129347
12.

Reirradiation in progressive high-grade gliomas: outcome, role of concurrent chemotherapy, prognostic factors and validation of a new prognostic score with an independent patient cohort.

Scholtyssek F, Zwiener I, Schlamann A, Seidel C, Meixensberger J, Bauer M, Hoffmann KT, Combs SE, von Bueren AO, Kortmann RD, Müller K.

Radiat Oncol. 2013 Jul 3;8:161. doi: 10.1186/1748-717X-8-161.

13.

Modification and optimization of an established prognostic score after re-irradiation of recurrent glioma.

Kessel KA, Hesse J, Straube C, Zimmer C, Schmidt-Graf F, Schlegel J, Meyer B, Combs SE.

PLoS One. 2017 Jul 5;12(7):e0180457. doi: 10.1371/journal.pone.0180457. eCollection 2017.

14.

Recurrent low-grade gliomas: the role of fractionated stereotactic re-irradiation.

Combs SE, Ahmadi R, Schulz-Ertner D, Thilmann C, Debus J.

J Neurooncol. 2005 Feb;71(3):319-23.

PMID:
15735924
15.

Validation of the prognostic Heidelberg re-irradiation score in an independent mono-institutional patient cohort.

Niyazi M, Flieger M, Ganswindt U, Combs SE, Belka C.

Radiat Oncol. 2014 Jun 3;9:128. doi: 10.1186/1748-717X-9-128.

16.

Survival gain with re-Op/RT for recurred high-grade gliomas depends upon risk groups.

Chun SJ, Park SH, Park CK, Kim JW, Kim TM, Choi SH, Lee ST, Kim IH.

Radiother Oncol. 2018 Aug;128(2):254-259. doi: 10.1016/j.radonc.2018.05.024. Epub 2018 Jun 21.

PMID:
29937212
17.

Treatment of recurrent high grade gliomas with hypofractionated stereotactic image-guided helical tomotherapy.

Kim B, Soisson E, Duma C, Chen P, Hafer R, Cox C, Cubellis J, Minion A, Plunkett M, Mackintosh R.

Clin Neurol Neurosurg. 2011 Jul;113(6):509-12. doi: 10.1016/j.clineuro.2011.02.001. Epub 2011 Mar 9.

PMID:
21392883
18.

A phase I dose escalation study of hypofractionated stereotactic radiotherapy as salvage therapy for persistent or recurrent malignant glioma.

Hudes RS, Corn BW, Werner-Wasik M, Andrews D, Rosenstock J, Thoron L, Downes B, Curran WJ Jr.

Int J Radiat Oncol Biol Phys. 1999 Jan 15;43(2):293-8.

PMID:
10030252
19.

External validation of a prognostic model estimating the survival of patients with recurrent high-grade gliomas after reirradiation.

Müller K, Henke G, Compter I, von Bueren AO, Friedrich C, Janssens G, Kramm CM, Hundsberger T, Paulsen F, Kortmann RD, Zwiener I, Baumert BG.

Pract Radiat Oncol. 2015 May-Jun;5(3):e143-50. doi: 10.1016/j.prro.2014.10.001. Epub 2014 Nov 18.

PMID:
25424325
20.

Reirradiation of gliomas under stereotactic conditions: Prognostic factors for survival without relapse or side effects, a retrospective study at Tours regional university hospital (France).

Lévy S, Chapet S, Scher N, Debbi K, Ruffier A, Bernadou G, Pointreau Y, Calais G.

Cancer Radiother. 2017 Dec;21(8):759-765. doi: 10.1016/j.canrad.2017.05.006. Epub 2017 Nov 8.

PMID:
29128197

Supplemental Content

Support Center